Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($3.07), $0.37 better than the analyst estimate of ($3.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $5.17 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Labcorp (LH) Tops Q2 EPS by 20c, Beats on Revenue; Offers FY26 EPS Guidance
• Omnicell (OMCL) Tops Q2 EPS by 52c ; Offers Guidance
• KKR & Co. (KKR) Tops Q2 EPS by 20c